Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) announced it will report financial results for the second quarter ended June 30, 2026, and provide a corporate update before markets open on Thursday, August 6, 2026.
The company will host a conference call and live webcast on August 6, 2026 at 8:30 a.m. ET to review the quarter and discuss corporate developments. Investors can access the live webcast via a registration link and through the Events & Presentations page in the Investors + Media section of www.praxismedicines.com. A replay of the second quarter earnings webcast will be available on the Events & Presentations page for approximately 90 days following the event.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 07 | Strategic partnership | Positive | +3.3% | Entered research collaboration and license agreement for a transdermal ulixacaltamide patch. |
| Jul 02 | Inducement grants | Neutral | -1.6% | Granted restricted stock units to new non-executive employees under inducement plan. |
| Jun 29 | FDA review extension | Negative | -4.5% | FDA extended relutrigine review after major amendment and additional sensitivity analyses. |
| Jun 22 | Breakthrough designation | Positive | +7.5% | Received FDA Breakthrough Therapy Designation supported by positive pediatric trial results. |
| Jun 04 | Conference presentation | Neutral | -4.1% | Scheduled corporate presentation at annual global healthcare conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive catalysts were followed by gains, while the review delay and routine announcements were followed by declines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026.
The Company will host a conference call and a live webcast to review the second quarter financial results and provide a corporate update on Thursday, August 6, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com.
A replay of the second quarter earnings webcast will be available on Praxis’ Events & Presentations page of the company’s website after each event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576